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ABSTRACT
Colorectal cancer (CRC) is a serious public health problem and non-invasive 
biomarkers improving diagnosis or therapy are strongly required. Circulating cell-free 
DNA (cfDNA) has been a promising target for this purpose. In this study, we evaluated 
the potential of long interspersed nuclear element-1 (LINE-1) hypomethylation as 
a blood biomarker for CRC. LINE-1 hypomethylation level in plasma cfDNA in 114 
CRC patients was retrospectively examined by absolute quantitative analysis of 
methylated alleles real-time PCR, and was expressed using LINE-1 hypomethylation 
index (LHI) [unmethylated copy number/ (methylated copy number + unmethylated 
copy number)]. Greater LHI values indicated enhanced hypomethylation. In our 
clinicopathological analysis, CRC patients with large tumors (≥6.0 cm), advanced 
N stage (≥2), and distant metastasis (M1) had statistically significantly higher 
cfDNA LHI than other CRC patients, suggesting cfDNA LHI as a disease progression 
biomarker for CRC. Furthermore, early stage I/II (n = 57) as well as advanced 
stage III/IV (n =57) CRC patients had significantly higher cfDNA LHI than healthy 
donors (n=53) [stage I/II: median 0.369 (95% confidence interval, 0.360–0.380) 
vs. 0.332 (0.325–0.339), P < 0.0001; stage III/IV: 0.372 (0.365–0.388) vs. 0.332 
(0.325–0.339), P < 0.0001]. The receiver operating characteristic analysis showed 
that cfDNA LHI had the detection capacity of CRC with area under the curve(AUC) of 
0.79 and 0.83 in stage I/II and stage III/IV CRC patients, respectively. The present 
study demonstrated for the first time the potential of plasma cfDNA LHI as a novel 
biomarker for CRC, particularly for early stage detection.
INTRODUCTION
Colorectal cancer (CRC) is a serious public health 
problem third leading cause of cancer-related deaths 
worldwide, owing to its high incidence and cancer-
related mortality [1]. A wide range of biomarkers, such 
as those for early detection, tumor progression, prediction 
of prognosis, and therapeutic monitoring have been 
investigated in the pursuit of the overall improvement of 
CRC patients’ outcomes.
In recent years, tumor-related circulating cell-free 
DNA (cfDNA) in plasma and serum has been a promising 
target for cancer biomarker studies. Clinical application of 
tumor-related cfDNA in plasma or serum has been termed 
“liquid biopsy” and utilized as a non-invasive method 
for the detection of tumor specific genetic and epigenetic 
alterations [2–5].
Aberrant DNA hypomethylation is one of the major 
DNA methylation abnormalities in cancer. It generally 
occurs in repetitive transposable DNA elements such 
as long interspersed nuclear element-1 (LINE-1) as 
well as short interspersed nucleotide elements (SINE or 
ALU), and is associated with genomic instability [6]. 
In particular, highly repetitive sequences of non-coding 
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genomic LINE-1 retrotransposon comprise approximately 
17–18% of the human genome, therefore, the methylation 
status of LINE-1 is considered to be an excellent indicator 
of the global DNA methylation status [7]. Many epigenetic 
studies have reported the LINE-1 hypomethylation in 
various cancers including CRC [8–12], breast cancer [13], 
gastric cancer [14, 15], melanoma [16], and hepatocellular 
carcinoma (HCC) [17]. In fact, previous studies have 
reported a correlation between the presence of LINE-1 
hypomethylation in CRC tissue with tumor progression 
[12] and poor prognosis [8, 9, 11, 18, 19].
Based on the data presented by Hoshimoto 
et al., increased levels of LINE-1 hypomethylation were 
observed in the serum cfDNA of stage III or IV malignant 
melanoma patients, compared to healthy donors [16]. 
Nonetheless, the LINE-1 hypomethylation status in plasma 
or serum cfDNA from CRC patients has not been further 
investigated. In this study, using absolute quantitative 
analysis of methylated alleles (AQAMA) real-time PCR 
method, we quantified LINE-1 hypomethylation level 
in plasma cfDNA from 114 CRC patients, and analyzed 
the association with various clinicopathological factors. 
Moreover, based on our previous finding of LINE-1 
hypomethylation manifestation at very early stages of 
CRC development [12], we hypothesized that LINE-1 
hypomethylation can be a novel biomarker for early CRC 
detection. To that end, we evaluated the potential of LINE-
1 hypomethylation in plasma cfDNA as a blood biomarker 
for early stage CRC detection.
RESULTS
Association between clinicopathological factors, 
cfDNA concentration and cfDNA LHI in CRC 
patients
Plasma cfDNA concentration and cfDNA LINE-
1 hypomethylation levels in 114 CRC patients who 
underwent surgical resection at The University of 
Tokyo Hospital between April 2012 and June 2014 were 
analyzed. The LINE-1 hypomethylation levels were 
evaluated by a modified absolute quantitative analysis of 
methylated alleles (AQAMA) real-time PCR assay, which 
were validated in our previous studies [12, 13, 16, 20], and 
was expressed as LINE-1 hypomethylation index (LHI); 
greater LHI indicated enhanced hypomethylation.
Table 1 exhibits the associations between clinico-
pathological features and both cfDNA concentration and 
cfDNA LHI. For cfDNA concentration, CRC patients with 
distant metastasis (M1) had significantly higher cfDNA 
concentration than those without distant metastasis (M0) 
[11.7 (11.1–15.1) vs. 10.2 (8.8–11.5) ng/mL, P = 0.03]. 
No statistically significant correlations were found 
between cfDNA concentration and tumor size, tumor 
location, tumor differentiation, lymphatic invasion, venous 
invasion, preoperative carcinoembryonic antigen (CEA) 
and carbohydrate antigen 19-9 (CA 19-9) levels, T stage 
and N stage.
Although no correlation was observed between 
cfDNA LHI and T stage when looking at cfDNA LHI, 
patients with tumors larger than 6.0 cm had significantly 
higher cfDNA LHI than patients with tumors smaller than 
6.0cm [0.385 (0.365–0.407) vs. 0.368 (0.362–0.374), 
P = 0.04]. In addition, patients with advanced N stage 
(≥2) and distant metastasis (M1) had significantly higher 
cfDNA LHI [N stage, 0.389 (0.371–0.411) vs. 0.368 
(0.357–0.373), P = 0.01; M stage, 0.388 (0.373–0.402) vs. 
0.368 (0.360–0.373), P = 0.03]. No correlation was found 
between cfDNA LHI and standard prognostic factors for 
CRC; tumor location, tumor differentiation, lymphatic 
invasion, venous invasion, and preoperative CEA and 
CA19-9 blood levels.
Comparison of demographic factors between 
healthy donors and CRC patients
We compared demographic factors (sex, age, BMI, 
and smoking status) between healthy donors (n = 53) 
and CRC patients (n = 114). As shown in Table 2, CRC 
patients were significantly older (P < 0.0001) than healthy 
donors and had a slightly higher rate of current smokers 
(P = 0.07), suggesting that age and smoking status may 
be potential confounding factors in our cohort. However, 
stratification analysis showed that in both healthy and CRC 
patients, neither cfDNA concentration nor cfDNA LHI 
were associated with all demographic factors including 
age and smoking status (Table 3). Based on these results, 
we included all healthy donors and CRC patients into our 
subsequent analysis.
Comparison of cfDNA concentration and cfDNA 
LHI between healthy donors and CRC patients
Figure 1 shows that cfDNA concentration and 
cfDNA LHI of CRC patients were significantly higher 
than those of healthy donors [cfDNA concentration, 11.1 
(9.8–11.6) vs. 7.7 (7.0–9.5) ng/mL, P = 0.0003, Figure 1A; 
cfDNA LHI, 0.371 (0.365–0.376) vs. 0.332 (0.325–0.339), 
P < 0.0001, Figure 1B].
Next we stratified CRC patients into early 
(stage I/II, n = 57) and advanced (stage III/IV, n = 57) 
groups. As shown in Figure 2, early stage I/II CRC 
patients had significantly higher cfDNA concentration 
and cfDNA LHI than healthy donors (n=53) [cfDNA 
concentration, 9.8 (8.6–11.5) vs. 7.7 (7.0–9.5) ng/mL, 
P = 0.03, Figure 2A; cfDNA LHI, 0.369 (0.360–0.380) 
vs. 0.332 (0.325–0.339), P < 0.0001, Figure 2B]. 
Similarly, advanced stage III/IV CRC patients had 
significantly higher cfDNA concentration and cfDNA 
LHI [cfDNA concentration, 11.5 (11.0–13.0) vs. 7.7 
(7.0–9.5) ng/mL, P = 0.0006, Figure 2A; cfDNA 
LHI, 0.372 (0.365–0.388) vs. 0.332 (0.325–0.339), 
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P < 0.0001, Figure 2B] than healthy donors. On the 
other hand, there were no statistically significant 
differences in cfDNA concentrations and cfDNA 
LHI between early and advanced stage CRC patients 
(cfDNA concentration, P = 0.31, Figure 2A; cfDNA 
LHI, P = 0.66, Figure 2B).
Table 1: Clinicopathological factors and cfDNA concentration and cfDNA LHI in CRC patients (n = 114)
Factors Number (%) cfDNA concentration, 
median (95% CI), ng/
mL
P value cfDNA LHI, median (95% 
CI)
P value
Tumor size 0.64 0.04
 <6.0 cm 85 (74.6%) 10.7 (9.6–11.7) 0.368 (0.362–0.374)
 ≥6.0 cm 29 (25.4%) 11.1 (9.1–14.5) 0.385 (0.365–0.407)
Location 0.08 0.77
 Right-side 34 (29.8%) 11.8 (9.8–16.6) 0.372 (0.36–0.388)
 Left-side 80 (70.2%) 10.4 (8.9–11.4) 0.371 (0.362–0.382)
Tumor differentiation 0.75 0.52
 WD 46 (40.4%) 10.9 (8.9–11.9) 0.373 (0.362–0.382)
 MD 60 (52.6%) 11.2 (9.1–12.6) 0.369 (0.357–0.384)
 PD/Mucinous 8 (7.0%) 10.6 (8.2–37.5) 0.387 (0.350–0.440)
Lymphatic invasion 0.97 0.54
 Negative 69 (60.5%) 10.5 (9.6–11.7) 0.373 (0.365–0.383)
 Positive 45 (39.5%) 11.5 (8.4–12.6) 0.370 (0.352–0.377)
Venous invasion 0.72 0.86
 Negative 25 (21.9%) 10.4 (8.1–12.6) 0.372 (0.361–0.376)
 Positive 89 (78.1%) 11.1 (9.8–11.8) 0.371 (0.362–0.383)
Preoperative CEA 0.17 0.57
 <5.0 ng/mL 52 (45.6%) 10.3 (8.2–11.5) 0.368 (0.364–0.382)
 ≥5.0 ng/mL 62 (54.4%) 11.3 (9.8–12.8) 0.373 (0.365–0.388)
Preoperative CA19-9 0.28 0.49
 <37 ng/mL 83 (72.8%) 10.4 (8.9–11.6) 0.371 (0.363–0.383)
 ≥37 ng/mL 31 (27.2%) 11.4 (9.4–15.1) 0.372 (0.349–0.381)
T stage 0.57 0.69
 T1–2 28 (24.6%) 10.1 (8.1–11.6) 0.372 (0.363–0.382)
 T3–4 86 (75.4%) 11.2 (9.8–11.9) 0.371 (0.360–0.383)
N stage 0.61 0.01
 N0–1 90 (78.9%) 10.6 (9.4–11.5) 0.368 (0.357–0.373)
 N2–3 24 (21.1%) 11.6 (8.9–15.1) 0.389 (0.371–0.411)
M stage 0.03 0.03
 M0 87 (76.3%) 10.2 (8.8–11.5) 0.368 (0.360–0.373)
 M1 27 (23.7%) 11.7 (11.1–15.1) 0.388 (0.373–0.402)
Abbreviations: cfDNA, circulating cell-free DNA; LHI, LINE-1 hypomethylation index; CRC, colorectal cancer; 
CI, confidence interval; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; CEA, 
carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.
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ROC curve analysis for the detection capacity of 
CRC
We examined the capacity of cfDNA concentration 
and cfDNA LHI as a biomarker for distinguishing CRC 
patients from healthy donors using receiver operating 
characteristic (ROC) curve analysis. The optimal cut-
off values were determined from the highest Youden 
index [21]. Using the cut-off value of 0.360, cfDNA 
LHI distinguished CRC patients with 65.8% sensitivity 







  Male 34 (64.1%) 65 (57.0%)
  Female 19 (35.9%) 49 (43.0%)
Age 50.6 (SD 19.3) 63.0 (SD 12.5) < 0.0001
BMI 22.5 (SD 2.5) 22.2 (SD 3.3) 0.43
Smoking status 0.07
  Current 7 (13.2%) 29 (25.4%)
  Former/None 46 (86.8%) 85 (74.6%)
Abbreviations: CRC, colorectal cancer; BMI, body mass index; SD, standard deviation.
Table 3: Demographic factors and cfDNA concentration and cfDNA LHI in healthy donors and CRC patients















cfDNA LHI P 
value
Sex 0.32 0.32 0.97 0.11
 Male 34 (64%) 8.0 (6.4–12.2) 0.331 (0.324–0.337) 65 (57%) 11.1 (9.1–11.7) 0.365 (0.357–0.374)
 Female 19 (36%) 7.7 (7.0–9.3) 0.334 (0.320–0.345) 49 (43%) 11.1 (8.9–12.8) 0.373 (0.370–0.391)
Age 0.93 0.48 0.15 0.96
 <60 years 34 (64%) 8.3 (4.9–10.4) 0.331 (0.315–0.344) 44 (39%) 9.7 (8.2–11.2) 0.372 (0.360–0.383)
 ≥60 years 19 (36%) 7.2 (6.6–10.0) 0.334 (0.325–0.344) 70 (61%) 11.5 (10.0–12.7) 0.371 (0.362–0.381)
BMI 0.80 0.52 0.51 0.27
 <25 45 (85%) 7.7 (6.4–9.5) 0.334 (0.325–0.340) 89 (78%) 11.1 (9.8–11.5) 0.373 (0.365–0.383)
 ≥25 8 (15%) 7.1 (6.6–23.9) 0.327 (0.316–0.355) 25 (22%) 11.7 (7.7–15.7) 0.367 (0.350–0.374)
Smoking 0.23 0.30 0.48 0.41
 Current 7 (13%) 10.6 (2.26–23.9) 0.326 (0.285–0.349) 29 (25%) 11.1 (7.7–12.6) 0.373 (0.360–0.389)
  Former/
None 46 (87%) 7.6 (7.0–9.3)
0.334 
(0.325–0.340) 85 (75%) 11.1 (9.8–11.9) 0.370 (0.362–0.376)
Note: cfDNA concentration and cfDNA LHI were expressed as median (95% confidence interval).
Abbreviations: cfDNA, circulating cell-free DNA; LHI, LINE-1 hypomethylation index; CRC, colorectal cancer; BMI, body mass index.
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and 90.0% specificity (area under the curve (AUC) 0.81, 
P < 0.0001, Figure 3A). Next we performed subgroup 
analysis for early (stage I/II) and advanced (stage III/
IV) CRC patients. cfDNA LHI distinguished early CRC 
patients with 63.2% sensitivity and 90.0% specificity 
(AUC 0.79, P < 0.0001, Figure 3B) and advanced CRC 
patients with 68.4% sensitivity and 90.0% specificity 
(AUC 0.83, P < 0.0001, Figure 3C).
Using the cut-off value of 10.7 ng/mL, cfDNA 
concentration distinguished early CRC patients 
with 42.1% sensitivity and 75.0% specificity (AUC 
0.64, P = 0.03) and advanced CRC patients with 63.2% 
sensitivity and 75.0% specificity (AUC 0.70, P = 0.003), 
rendering it less adequate for CRC detection than cfDNA 
LHI.
Comparison of sensitivity between CEA and 
cfDNA LHI for CRC detection
We assessed the capacity of a standard blood CEA 
biomarker for CRC detection in CRC patients. Table 4 
shows that the sensitivity of CEA for CRC detection 
was 40.4% in stage I/II CRC with the conventional 
cut-off value of 5.0 ng/mL. On the other hand, the 
sensitivity of cfDNA LHI was 63.2% in stage I/II CRC, 
indicating its higher sensitivity for early CRC detection 
than CEA.
DISCUSSION
In this study, we examined 114 plasma samples of 
CRC patients, and quantified LINE-1 hypomethylation 
status in plasma cfDNA by AQAMA PCR method. 
The efficacy of this assay has been validated in several 
previous studies [12, 13, 16, 20]. We confirmed that even 
early stage I/II as well as advanced stage III/IV CRC 
patients had significantly higher cfDNA LHI than healthy 
donors. Detection of early stage I/II CRC through cfDNA 
LHI was accomplished with 63.2% sensitivity and 90.0% 
specificity (AUC 0.79), suggesting the potential utility of 
cfDNA LHI as a blood biomarker for early CRC detection.
Colonoscopy is the gold standard for CRC 
diagnosis, given its more than 90% sensitivity and 
specificity [22]. However, due to its invasive nature and 
possible morbid complications such as bowel perforation, 
most patients are reluctant to undergo colonoscopy. 
At present, fecal occult blood test (FOBT) is the most 
frequently used non-invasive modality in CRC screening 
program in the USA. Prospective randomized controlled 
trials showed that FOBT screening reduced CRC-related 
mortality [23]. Furthermore, recent fecal immunochemical 
test (FIT) has shown high CRC detectability [24], while 
the utility of stool-based DNA assays has been reported as 
a new application for CRC diagnosis [25]. Nonetheless, 
FOBT has some limitations, such as its relatively low 
Figure 1: Comparison of cfDNA concentration and cfDNA LHI between healthy donors and CRC patients. A. cfDNA 
concentration of 114 CRC patients was significantly higher than that of 53 healthy donors (Mann–Whitney U test, P = 0.0003). B. cfDNA 
LHI of 114 CRC patients was significantly higher than that of 53 healthy donors (Mann–Whitney U test, P < 0.0001). The horizontal line 
represents the median value.
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sensitivity for early-stage or proximal colon cancer [24, 
26]. Moreover, adherence rate to the CRC screening 
program based on FOBT and colonoscopy remains low at 
around 50% [27, 28], and it is reported that many people 
who avoid current FOBT program prefer a simple blood-
based test instead [29]. Our non-invasive blood-based 
method would be particularly beneficial for patients who 
are averse to stool-based test.
Figure 3: ROC curve analysis assessing the capacity of cfDNA LHI to distinguish CRC patients from healthy donors. 
A. ROC curve analysis of cfDNA LHI for all stage CRC patients. Using the cut-off value of 0.360, cfDNA LHI could distinguish CRC 
patients with 65.8% sensitivity and 90.0% specificity (AUC 0.81, P < 0.0001). The optimal cut-off value was defined as the highest Youden 
index [(specificity + sensitivity) − 1]. B. ROC curve analysis for early CRC patients (stage I/II). cfDNA LHI showed sensitivity 63.2%, 
specificity 90.0% (AUC 0.79, P < 0.0001). C. ROC curve analysis for advanced CRC patients (stage III/IV). cfDNA LHI showed sensitivity 
68.4%, specificity 90.0% (AUC 0.83, P < 0.0001).
Figure 2: Comparison of cfDNA concentration and cfDNA LHI between healthy donors and early (stage I/II) and 
advanced (stage III/IV) CRC patients. A. A nonparametric multiple comparison Steel-Dwass test showed that both early stage I/II 
and advanced stage III/IV CRC patients had significantly higher cfDNA concentration than healthy donors [stage I/II, 9.8 (8.6–11.5) vs. 
7.7 (7.0–9.5) ng/mL, P = 0.03; stage III/IV, 11.5 (11.0–13.0) vs. 7.7 (7.0–9.5) ng/mL, P = 0.0006]. There was no statistically significant 
difference of cfDNA concentration between early and advanced CRC patients (P = 0.31). The horizontal line represents the median value. 
B. A nonparametric multiple comparison Steel-Dwass test showed that both early stage I/II and advanced stage III/IV CRC patients had 
significantly higher cfDNA LHI than healthy donors [stage I/II, 0.369 (0.360–0.380) vs. 0.332 (0.325–0.339), P < 0.0001; stage III/IV, 
0.372 (0.365–0.388) vs. 0.332 (0.325–0.339), P < 0.0001]. There was no statistically significant difference of cfDNA LHI between early 
and advanced CRC patients (P = 0.66). The horizontal line represents the median value.
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Most blood methylation biomarkers target a single 
chromosome region. As a result, the amount of target 
cfDNA fragments in blood circulation can be very 
limited particularly after bisulfite conversion [30], raising 
concerns about false negative results. To increase the 
assay sensitivity, a large amount of plasma is sometimes 
needed; commercially offered mSEPT9 test such as Epi 
proColon (Epigenomics AG, Berlin, Germany) requires 
3.5 mL of plasma [31]. Conversely, the abundant number 
of LINE-1 copies in the human genome enabled us to 
quantify the absolute methylation level with 0.5 mL of 
plasma without any additional applications such as digital 
PCR or next generation sequencing. Moreover, our LINE-
1 assay is particularly advantageous when using plasma, 
which is preferred due to its relatively low genomic DNA 
contamination, but has lower amount of cfDNA than 
serum [3].
Although the sensitivity and specificity of CEA are 
considered to be insufficient for CRC detection, CEA is the 
most routinely measured blood biomarker for CRC. Our 
data showed that cfDNA LHI had higher sensitivity for early 
stage I/II CRC than CEA. In a recent systematic review [32], 
the pooled specificity of CEA for CRC detection was 88.0% 
with the conventional cut-off value of 5.0 ng/mL, which 
is similar to our results’ specificity of 90.0%, suggesting 
cfDNA LHI to be more suitable for early CRC detection than 
CEA. Several previous studies have also reported the utility 
of simple quantitative assessment of cfDNA concentration 
for CRC diagnosis [33–36]. However, in our cohort, cfDNA 
concentration demonstrated lower detectability of CRC 
when compared to cfDNA LHI. 
Additionally, considering that cfDNA concentration 
can be affected by various non-malignant diseases 
and physiological conditions [3], its diagnostic utility 
for CRC is further discredited. We did not observe a 
statistically significant difference in cfDNA LHI and 
cfDNA concentrations between early (stage I/II) and 
advanced (stage III/IV) CRC patients. Although LINE-
1 hypomethylation occurs at very early stage in CRC 
development [12], several studies have reported that 
LINE-1 hypomethylation status in CRC tissue was 
independent of CRC stage [8, 11, 37, 38]. Overall, LINE-
1 hypomethylation is believed to remain relatively stable 
during CRC progression [39]. These findings may partially 
explain our results that no difference of cfDNA LHI was 
observed between early and advanced CRC patients. On 
the other hand, CRC patients with highly advanced stage 
(N ≥2 and M1) and large tumor size (≥6.0 cm) showed 
significantly higher cfDNA LHI than other patients in 
the study, implying the possibility of cfDNA LHI as a 
biomarker for advanced CRC progression and/or distant 
metastasis.
Four limitations of this study must be noted. 
First, LINE-1 hypomethylation in plasma cfDNA is not 
always specific to CRC. Similar to other methylation 
blood biomarkers, no CRC-specific DNA methylation 
biomarkers have been identified at this time. However, 
considering the recent high incidence and cancer-related 
mortality of CRC, it may be beneficial to employ our 
non-invasive blood assay and easily measure cfDNA 
as a first step towards CRC detection and recurrence 
after surgery. Repetitive analysis at specific intervals of 
cfDNA LHI may also be useful for disease monitoring 
as in early detection of recurrence following the surgical 
resection of CRC in high risk patients. Second, in 
comparison with healthy donors, we assessed four 
demographic factors (sex, age, BMI, and smoking 
factors) that may influence cfDNA LHI. However, DNA 
methylation can also be affected by other factors such 
as race, alcohol consumption, physical activity, and diet 
[40], whose associations with LINE-1 hypomethylation 
remain undetermined [40]. Third, during the median 
follow-up of 24.6 months, eight patients died of CRC 
(one stage II, one stage III and six stage IV) and 13 
patients in stage I–III experienced tumor recurrence after 
the curative resection (four stage II and nine stage III). 
However, we could not detect a statistically significant 
correlation between patients’ prognosis and cfDNA LHI. 
This may be due to the short follow-up period. Finally, 
this was a prospective pilot study from a single institute 
small patient cohort. Therefore, prospective studies and 
multi-institutional validation are needed in the future.
In conclusion, the present study is the first report 
demonstrating the potential of LINE-1 hypomethylation 
in plasma cfDNA as a blood biomarker for CRC detection, 
particularly for early stages of the disease.








  Sensitivity 54.4% (62/114) 40.4% (23/57) 68.4% (39/57)
cfDNA LHI
  Sensitivity 65.8% (75/114) 63.2% (36/57) 68.4% (39/57)




Patients and healthy donors
We analyzed a total of 114 plasma samples obtained 
from consecutive CRC patients who underwent surgical 
tumor resection at the University of Tokyo Hospital 
between April 2012 and June 2014, whose plasma samples 
were available for analysis. Exclusion criteria for this 
study consisted of any patients with a history of malignant 
disease or colitis associated CRC, as well as patients 
receiving any preoperative treatments or radiotherapy. 
No other malignant tumors except CRC were found 
in patients after preoperative examinations. A detailed 
database of clinicopathological information was developed 
for statistical analysis. The cancer’s histological grade 
and clinical stage were identified in accordance with the 
seventh edition of the TNM classification of the Union for 
International Cancer Control (UICC).
Fifty-three healthy donors were also analyzed. All 
healthy donors were having medical check-ups periodically 
and had no history of cancer or bowel symptoms, representing 
a normal Japanese adult population cohort at average risk of 
CRC. For the healthy donors > 50 yrs, prior to blood sample 
collection, colonoscopy examination was performed to 
confirm the absence of advanced adenoma or CRC.
The study protocol was approved by the ethics 
committee of the University of Tokyo Hospital and written 
informed consents were obtained from all participating 
patients.
Specimen demographics
Prior to the operation, peripheral blood (10 mL) of 
each patient was collected into EDTA-containing blood 
tubes. Plasma was obtained by centrifugation of the whole 
blood samples at 1,500 g for 10 min and immediately 
stored at −80°C until analysis. Similarly, peripheral blood 
collection (5mL) of healthy donors was followed by 
extraction of plasma and storage as describe above.
cfDNA extraction from plasma
Plasma samples were thawed and microcentrifuged 
at 4°C and 12,000 g for 3 min to remove cell debris. 
cfDNA was extracted from plasma as previously 
described [12, 16, 41]. In brief, aliquots of 500 µL plasma 
were diluted with 0.9% NaCl and mixed with a premix 
consisting of proteinase K and SDS. After incubation at 
50°C for 3 h, cfDNA was treated with phenol–chloroform-
isoamyl alcohol (25:24:1, pH 8.0; Nippon Gene) and 
precipitated with isopropanol.
Measurement of cfDNA concentration
DNA concentration of each plasma sample was 
quantified using Varioskan Flash (ThermoFisher Scientific) 
and a Quani-iT PicoGreen dsDNA Assay Kit (Life 
Technologies) according to the manufacturer’s instructions.
Sodium bisulfite conversion
Sodium bisulfite conversion was performed as 
previously described [42]. In brief, up to 500 ng of DNA 
was denatured in 0.3 M NaOH at 37°C for 15 min and 
dissolved in a solution consisting of 3.06 M sodium 
bisulfite (Sigma-Aldrich) and 0.5 mM hydroquinone 
(Sigma-Aldrich) adjusted to pH 5.0 with NaOH. The 
solution was subjected to 15 cycles of denaturation at 95°C 
for 30 s and incubation at 50 °C for 15 min, desalted and 
desulfonated on a Zymo-Spin Column (Zymo Research), 
and eluted with 20 µL of Tris-EDTA buffer.
Measurement of LINE-1 hypomethylation status
The hypomethylation status of LINE-1 was 
evaluated by a modified absolute quantitative analysis 
of methylated alleles (AQAMA) assay [12, 13, 16, 20]. 
In brief, AQAMA requires forward and reverse primers 
for amplifying a targeted sequence, methylation-specific 
and unmethylation-specific TaqMan probes with minor 
groove binder (MGB). The targeted sequence of LINE-
1 was 148 bp in size and located in the promoter region 
of LINE-1. LINE-1 hypomethylation of this targeted 
region in early CRC tissue had already been confirmed 
in our previous study [12]. Primers and probes were 
purchased from Life Technologies. The following sets of 
primers were used: forward primer, 5′-GGGTTTATTTT 
ATTAGGGAGTGTTAGA-3′; reverse primer, 5′-TCAC 
CCCTTTCTTTA ACTCAAA-3′; methylation-specific 
probe, VIC-5′-TGCGCGAGTCGAAGT-3′-MGB; and 
unmethylation-specific probe, FAM-5′-TGTGTGAGT 
TGAAGTAGGG-3′-MGB. The AQAMA PCR reaction 
was performed with a 7500 Fast Real-Time PCR system 
(Life Technologies). All measurements were taken 
in triplicate of 20 µL consisting of 2 µL of bisulfite-
converted DNA template, 10µL of KAPA PROBE FAST 
qPCR Master Mix (KAPA Biosystems), 0.4 µmol/L of 
the forward and reverse primer, and 0.25µmol/L of each 
MGB probe. The PCR conditions were as follows: 95°C 
for 3 min, followed by 40 cycles at 95°C for 15 s, and 
60°C for 60 s. The absolute copy number of each sample 
was estimated from a standard curve with known copy 
numbers (10*6 to 10*1 copies).
The LINE-1 hypomethylation index (LHI) was 
defined as the unmethylated copy number/ (methylated 
copy number + unmethylated copy number), so that a 
greater LHI indicated enhanced LINE-1 hypomethylation. 
This LHI was used for the analysis.
Construction of control plasmid
The universal unmethylated and methylated 
control DNA was synthesized from peripheral blood 
Oncotarget11914www.impactjournals.com/oncotarget
DNA of healthy donors using illustra GeomiPhi V2 DNA 
Amplification Kit (GE Healthcare) and M.SssI CpG 
methyltransferase (New England BioLabs), respectively. 
Both control DNA were bisulfite modified and were then 
amplified by PCR with the primer set of targeted region 
of LINE-1. The completely methylated and unmethylated 
PCR products were ligated into pCR 2.1-TOPO cloning 
vector (Life Technologies).
Methylated control plasmid was digested by Hind 
III and blunted with DNA Blunting Kit (TAKARA BIO), 
and then digested by Xho I. After the BamH I site of 
unmethylated control plasmid being destroyed by blunting 
with DNA Blunting Kit and self-ligation, unmethylated 
control plasmid was digested by EcoR V and Xho I. 
The Xho I and blunted Hind III fragment of methylated 
control DNA was ligated into the Xho I and EcoR V site 
of unmethylated control plasmid vector. Next the plasmid 
was linearized by BamH I digestion.
The constructed plasmid contained both methylated 
and unmethylated control sequences at the ratio of 1:1, 
and was PCR-amplified to make both methylated and 
unmethylated standard curves with methylation-specific 
and unmethylation-specific MGB probes in the same 
PCR well, enabling us to perform more accurate absolute 
quantification of methylated and unmethylated copy 
numbers.
Statistical analysis
All analyses results presented in this study were 
based on biostatistical assessment. All statistical 
analyses were performed using JMP Pro version 10 
software (SAS Institute). cfDNA concentration and 
cfDNA LHI were represented as the median with 95% 
confidence interval (CI), and were analyzed using 
Mann–Whitney U test (two groups) or Kruskal–Wallis 
test (multiple groups). The age and BMI of healthy 
donors and CRC patients were expressed as the means 
with SD, while Mann–Whitney U test was used for 
comparisons. Categorical variables were represented 
as numbers (%) and analyzed by Pearson’s chi-squared 
test. In ROC curve analysis, the optimal cut-off value 
was defined as the highest Youden index [(specificity + 
sensitivity) − 1] [21]. Steel-Dwass test was performed 
for the nonparametric multiple comparison of cfDNA 
concentration and cfDNA LHI in healthy donors and 
CRC patients. Probability values (P) < 0.05 were 
considered statistically significant.
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